MedinCell S.A. (MEDCL.PA)

EUR 16.8

(5.53%)

Market Cap (In EUR)

491.05 Million

Revenue (In EUR)

9.16 Million

Net Income (In EUR)

-25.03 Million

Avg. Volume

70.47 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.5-19.0
PE
-
EPS
-
Beta Value
1.2
ISIN
FR0004065605
CUSIP
F6104D107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Christophe Douat
Employee Count
-
Website
https://www.medincell.com
Ipo Date
2018-10-08
Details
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.